Maker Halts Distribution of Generic Zantac Due to Possible Carcinogen
THURSDAY, Sept. 19, 2019 (HealthDay News) — Novartis, the maker of a generic form of the popular heartburn drug Zantac, said Wednesday it will cease distribution of the medicine after investigations suggested that generic and branded versions contain a known carcinogen. A distribution halt is not the same as aContinue Reading